S A Eccles
Overview
Explore the profile of S A Eccles including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1774
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beloueche-Babari M, Box C, Arunan V, Parkes H, Valenti M, De Haven Brandon A, et al.
Br J Cancer
. 2015 Mar;
112(7):1206-14.
PMID: 25742484
Background: Acquired resistance to molecularly targeted therapeutics is a key challenge in personalised cancer medicine, highlighting the need for identifying the underlying mechanisms and early biomarkers of relapse, in order...
2.
Moore A, Faisal A, de Castro D, Bavetsias V, Sun C, Atrash B, et al.
Leukemia
. 2012 Feb;
26(7):1462-70.
PMID: 22354205
Acquired resistance to selective FLT3 inhibitors is an emerging clinical problem in the treatment of FLT3-ITD(+) acute myeloid leukaemia (AML). The paucity of valid pre-clinical models has restricted investigations to...
3.
Eccles S
Methods Mol Med
. 2011 Feb;
58:161-71.
PMID: 21340856
Metastasis is the most devastating aspect of cancer, and the major reason for treatment failure. It is perhaps surprising, therefore, that it is only relatively recently that a wide variety...
4.
Butler J, Milliken D, Dina R, Eccles S, Maghami S, Jameson C, et al.
Eur J Gynaecol Oncol
. 2010 Nov;
31(5):510-3.
PMID: 21061790
Objective: To determine whether there is a node count which can define an adequate inguinofemoral lymphadenectomy (IFL) in primary VSCC. Methods: A retrospective and prospective review of patients with node...
5.
Workman P, Aboagye E, Balkwill F, Balmain A, Bruder G, Chaplin D, et al.
Br J Cancer
. 2010 May;
102(11):1555-77.
PMID: 20502460
Animal experiments remain essential to understand the fundamental mechanisms underpinning malignancy and to discover improved methods to prevent, diagnose and treat cancer. Excellent standards of animal care are fully consistent...
6.
Eccles S
Curr Opin Mol Ther
. 2009 Jul;
1(6):737-44.
PMID: 19629871
Imaging of cancer by radioimmunoscintigraphy (RIS) following administration of radiolabeled monoclonal antibodies (mAbs) or fragments has been under development for two decades. Efficacy is a function of many variables: antigen...
7.
Pandher R, Ducruix C, Eccles S, Raynaud F
J Chromatogr B Analyt Technol Biomed Life Sci
. 2008 Dec;
877(13):1352-8.
PMID: 19101213
The reproducibility of a metabolomics method has been assessed to identify changes in tumour cell metabolites. Tissue culture media extracts were analyzed by reverse phase chromatography on a Waters Acquity...
8.
Peak J, Jones N, Hobbs S, Katan M, Eccles S
Oncogene
. 2007 Nov;
27(20):2823-32.
PMID: 18037957
Phospholipase Cgamma1 (PLCgamma1) is activated downstream of a variety of extracellular stimuli and has previously been implicated in the regulation of motility responses central to tumour cell invasion. In this...
9.
Kirby A, AHern R, DAmbrosio C, Tanay M, Syrigos K, Rogers S, et al.
Br J Cancer
. 2006 Feb;
94(5):631-6.
PMID: 16495923
To assess the level of activity and toxicity of gefitinib (ZD1839, Iressatrade mark) in a population of patients with locally recurrent and/or metastatic head and neck cancer. Patients were recruited...
10.
George M, Tutton M, Abulafi A, Eccles S, Swift R
Clin Exp Metastasis
. 2003 Jan;
19(8):735-8.
PMID: 12553380
Angiogenic cytokines in the plasma and serum of cancer patients may serve as 'surrogate' markers of tumour neoangiogenesis. Serum VEGF correlates with disease stage in colorectal cancer (CRC), but the...